Pain Therapeutics, Durect soar on Remoxy hopes


News that Pfizer (PFE -1.6%) is planning a Phase 1 trial of Remoxy sends shares of Pain Therapeutics (PTIE +29.3%) and Durect (DRRX +14.3%) sharply higher in midday trading.

Many began to question the drug's fate after PFE indicated in May that a response to the FDA's latest Reomxy CRL likely would not be submitted "before mid-2015."

See SA Contributor Red Acre Investments' latest article on Remoxy

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs